S. Shak

2.5k total citations · 1 hit paper
40 papers, 1.8k citations indexed

About

S. Shak is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Shak has authored 40 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Cancer Research, 22 papers in Oncology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Shak's work include Breast Cancer Treatment Studies (23 papers), Advanced Breast Cancer Therapies (14 papers) and Cancer Genomics and Diagnostics (11 papers). S. Shak is often cited by papers focused on Breast Cancer Treatment Studies (23 papers), Advanced Breast Cancer Therapies (14 papers) and Cancer Genomics and Diagnostics (11 papers). S. Shak collaborates with scholars based in United States, Germany and Switzerland. S. Shak's co-authors include George W. Sledge, Kim Margolin, Daniel C. Adelman, Moshe Talpaz, Eric Holmgren, Robert S. Benjamin, Michael S. Gordon, Frederick L. Baehner, G. W. Sledge and Carl Yoshizawa and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

S. Shak

39 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

2001 744 citations Michael S. Gordon, Kim Margolin et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by S. Shak

Since Specialization

Citations

This map shows the geographic impact of S. Shak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Shak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Shak more than expected).

Fields of papers citing papers by S. Shak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Shak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Shak. The network helps show where S. Shak may publish in the future.

Co-authorship network of co-authors of S. Shak

This figure shows the co-authorship network connecting the top 25 collaborators of S. Shak. A scholar is included among the top collaborators of S. Shak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Shak. S. Shak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial 2020 ·Breast Cancer Research ·Cornelia Kolberg-Liedtke, Oleg Gluz, (unknown), Friedrich Feuerhake, Hans Kreipe, Michael Clemens, Benno Nuding, Wolfram Malter, Toralf Reimer, Rachel Wuerstlein, Monika Graeser, S. Shak, Ulrike Nitz, Ronald Kates, Matthias Christgen, Nadia Harbeck	19
2	Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer 2016 ·European Journal of Cancer ·Oleg Gluz, (unknown), (unknown), (unknown), Michael Clemens, Stefan Kraemer, Benno Nuding, Bahriye Aktas, Sherko Küemmel, Toralf Reimer, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, C Liedtke, Cecilia Svedman, S. Shak, Rachel Wuerstlein, (unknown), Nadia Harbeck	5
3	Breast cancer-specific survival in >4,600 patients with lymph node-positive (LN+) hormone receptor-positive (HR+) invasive breast cancer (BC) and 21-gene recurrence score® (RS) results in the SEER registries 2016 ·Annals of Oncology ·Dave P. Miller, Megan C. Roberts, Valentina I. Petkov, S. Shak, Nadia Howlader, Kathleen A. Cronin, Lynne Penberthy	3
4	Abstract P5-15-01: Breast cancer specific survival in 38,568 patients with node negative hormone receptor positive invasive breast cancer and oncotype DX recurrence score results in the SEER database 2016 ·Cancer Research ·S. Shak, (unknown), (unknown), Nadia Howlader, (unknown), (unknown), Nicola Schussler, Kathleen A. Cronin, (unknown), Lynne Penberthy	9
5	Abstract P4-11-01: Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial 2015 ·Cancer Research ·Ulrike Nitz, Oleg Gluz, Ronald Kates, Daniel Hofmann, Hans Kreipe, Matthias Christgen, S. Shak, Michael Clemens, Stefan Kraemer, Bahriye Aktas, Sherko Küemmel, Toralf Reimer, M. Kusche, Volker Heyl, (unknown), Marianne Just, Cornelia Liedtke, Rachel Wuerstlein, Nadia Harbeck	3
6	Validation of the 12-Gene Colon Cancer Recurrence Score as a Predictor of Recurrence Risk in Stage II and III Rectal Cancer Patients 2014 ·JNCI Journal of the National Cancer Institute ·Marlies S. Reimers, Peter J.K. Kuppen, Mark Lee, Margarita Lopatin, (unknown), Hein Putter, Kim M. Clark-Langone, Gerrit‐Jan Liefers, S. Shak, Cornelis J.�H. van de Velde	16
7	A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast 2013 ·JNCI Journal of the National Cancer Institute ·Lawrence J. Solin, Robert P. Gray, Frederick L. Baehner, Steven M. Butler, Lorie L. Hughes, Carl Yoshizawa, Diana B. Cherbavaz, S. Shak, David L. Page, G. W. Sledge, Nancy E. Davidson, J. N. Ingle, Edith A. Perez, W. C. Wood, Joseph A. Sparano, S Badve	335
8	Abstract P2-10-08: Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial 2012 ·Cancer Research ·Oleg Gluz, (unknown), (unknown), Matthias Christgen, C Liedtke, S. Shak, Michael Clemens, Marwa Rashad Salem, B Liedtke, Bahriye Aktas, Susanne Markmann, Christoph Uleer, Doris Augustin, Christoph Thomssen, Ulrike Nitz, (unknown)	3
9	Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer 2011 ·British Journal of Cancer ·Joffre Baker, Debjani Dutta, Drew Watson, Tara Maddala, Brian Munneke, S. Shak, (unknown), (unknown), Christopher Harbison, Edwin Clark, David J. Mauro, Shirin Khambata‐Ford	81
10	P1-07-11: Consistency and Control in Clinical Assay Technology over Time: The Oncotype DX Recurrence Score and Assessment of Single Gene Expression Levels. 2011 ·Cancer Research ·(unknown), (unknown), J. M. Anderson, Jimmy D. Ballard, Vivian Tan, S. Shak	3
11	Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial. 2011 ·Journal of Clinical Oncology ·Tom Degenhardt, Oleg Gluz, (unknown), Ronald Kates, C Liedtke, S. Shak, Michael Clemens, Doris Augustin, Ulrike Nitz, Nadia Harbeck, (unknown)	3
12	Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories 2010 ·Journal of Clinical Oncology ·Frederick L. Baehner, Ninah Achacoso, Tara Maddala, S. Shak, Charles P. Quesenberry, Lynn C. Goldstein, Allen M. Gown, Laurel A. Habel	91
13	The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel. 2010 ·Journal of Clinical Oncology ·(unknown), Nicky Liebermann, Shulamith Rizel, (unknown), (unknown), Lior Soussan‐Gutman, Roberto Bugarini, (unknown), S. Shak	3
14	GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer. 2009 ·Cancer Research ·(unknown), Robert P. Gray, LJ Goldstein, BH Childs, Roberto Bugarini, Simone M. Rowley, Jennifer H.E. Baker, S. Shak, S Badve, (unknown), EA Perez, L. Shulman, Sabata Martino, (unknown), NE Davidson	3
15	Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. 2009 ·Cancer Research ·Mitch Dowsett, J Cuzick, Craig Wales, JF Forbes, Louise Mallon, Janine Salter, Edel Quinn, Roberto Bugarini, (unknown), S. Shak, (unknown)	25
16	Population-based study of hormone receptor status comparing OncotypeDX with standard immunohistochemistry 2009 ·Breast Cancer Research ·(unknown), Tara Maddala, C. Alexander, Gown Am, (unknown), (unknown), S. Shak, (unknown), Laurel A. Habel	3
17	Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer 2008 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Tara Maddala, S. Shak, Eric K. Rowinsky, Lei Xu, (unknown), David J. Mauro, Shirin Khambata‐Ford	8
18	Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue 2006 ·Breast Cancer Research and Treatment ·Lida A. Mina, (unknown), Sunil Badve, (unknown), Joffre Baker, Maureen Cronin, Drew Watson, (unknown), George W. Sledge, S. Shak, Kathy D. Miller	80
19	Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer breakdown → 2001 ·Journal of Clinical Oncology ·Michael S. Gordon, Kim Margolin, Moshe Talpaz, George W. Sledge, Eric Holmgren, Robert S. Benjamin, (unknown), S. Shak, Daniel C. Adelman	744
20	Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. 1999 ·PubMed ·S. Shak	227

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact